Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing centralized hospital monitoring of clinical safety of Shuganning injection
ChiCTR2100046253Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Chinese Medicine
- Start
- May 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of shuganning in adverse drug reaction (ADR), sponsored by First Affiliated Hospital of Henan University of Chinese Medicine. Primary endpoints: Type, manifestations, and incidence of adverse drug reactions to Shuganning injection, Severity, prognosis, and outcomes of adverse reactions to Shuganning injection and 2 more. Started May 2021; status: recruiting.
02
Drugs
shuganning
03
Conditions
adverse drug reaction (ADR)
Beyond the preview
Go deeper on ChiCTR2100046253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046253.